134 filings
Page 2 of 7
6-K
CALT
Calliditas Therapeutics AB
28 Apr 23
Current report (foreign)
4:05pm
20-F
2022 FY
CALT
Calliditas Therapeutics AB
Annual report (foreign)
26 Apr 23
4:54pm
6-K
CALT
Calliditas Therapeutics AB
13 Mar 23
Current report (foreign)
4:01pm
6-K
CALT
Calliditas Therapeutics AB
13 Mar 23
Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA Nephropathy
6:01am
6-K
CALT
Calliditas Therapeutics AB
23 Feb 23
Current report (foreign)
4:07pm
SC 13G/A
Biotechnology Value Fund L P
14 Feb 23
Calliditas Therapeutics AB / BIOTECHNOLOGY VALUE FUND L P ownership change
11:50am
6-K
CALT
Calliditas Therapeutics AB
2 Feb 23
Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathy
4:06pm
SC 13G/A
Fjarde Ap-fonden /fourth Swedish National Pension Fund
1 Feb 23
Calliditas Therapeutics AB / FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND ownership change
4:55pm
6-K
CALT
Calliditas Therapeutics AB
31 Jan 23
Current report (foreign)
4:44pm
SC 13G
Swedbank Robur Fonder AB
26 Jan 23
Calliditas Therapeutics AB / Swedbank Robur Fonder AB ownership change
10:27am
6-K
CALT
Calliditas Therapeutics AB
30 Dec 22
Current report (foreign)
4:30pm
6-K
CALT
Calliditas Therapeutics AB
13 Dec 22
Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in Japan
4:30pm
6-K
CALT
Calliditas Therapeutics AB
15 Nov 22
Calliditas’ partner Everest Medicine’s New Drug Application for Nefecon is accepted by the China NMPA
4:05pm
6-K
CALT
Calliditas Therapeutics AB
14 Nov 22
Current report (foreign)
5:25pm
6-K
CALT
Calliditas Therapeutics AB
21 Oct 22
Calliditas Therapeutics’ nomination committee composition for the AGM 2023
4:01pm
6-K
CALT
Calliditas Therapeutics AB
20 Sep 22
Calliditas’ partner STADA launches the first medicine authorized in the EU for treating primary IgA nephropathy
4:01pm
6-K
CALT
Calliditas Therapeutics AB
19 Aug 22
Interim Report January 1ST – June 30TH 2022
7:55am
6-K
CALT
Calliditas Therapeutics AB
29 Jul 22
Current report (foreign)
4:03pm
6-K
CALT
Calliditas Therapeutics AB
15 Jul 22
European Commission approves Kinpeygo® for adults with primary IgA nephropathy
4:01pm
6-K
CALT
Calliditas Therapeutics AB
12 Jul 22
Calliditas announces additions to the management team
4:01pm